Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial
暂无分享,去创建一个
F. Awan | H. Kluin-Nelemans | T. George | K. Sotlar | A. Reiter | D. Sternberg | P. Valent | M. Mauro | E. Stanek | J. Gotlib | O. Hermine | H. Horny | C. Akin | E. Hexner | M. Villeneuve | Fabienne Emery-Salbert | E. Stanek | K. Hartmann